Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
184
resultados
Última actualización
14/03/2025 [07:07:00]
Resultados 25 a 50 de 184
Resumen de: US2025073259A1
A therapeutic material active against SARS-COV 2 and other microbial pathogens and method of administering the same.
Resumen de: AU2023334060A1
The present disclosure is directed to antibodies and antigen binding fragments thereof, or combinations of antibodies and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. The disclosure contemplates conjugates of anti-CoV-S antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.
Resumen de: AU2023336178A1
The invention relates to a polynucleotide encoding a) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein; and/or b) at least one non-structural SARS-CoV-2 protein selected from the group consisting of non-structural protein 7, non-structural protein 8, non-structural protein 9, non-structural protein 10, non-structural protein 11, non-structural protein 12, an endoribonuclease, and a 2'-O-methyltransferase, wherein the polynucleotide comprises or consists of at least one sequence part comprising codon-pair deoptimizations in comparison to the SARS-CoV-2 genome, and wherein the polynucleotide further comprises a furin cleavage site modification resulting in a loss of a furin cleavage site being naturally present in the SARS-CoV-2 genome. The invention further relates to a live attenuated SARS- CoV-2 comprising this polynucleotide, to a vaccine comprising this live attenuated SARS-CoV-2, as well as to associated methods.
Resumen de: AU2023313034A1
The disclosure provides compositions and methods comprising selective inhibitors of Rho-associated coiled-coil kinase 2 (ROCK2) for use in the treatment of viral infections, particularly coronavirus infections such as SARS-CoV-2, and in the treatment of sequelae resulting from the viral infection, including sequelae resulting from coronavirus infection.
Resumen de: US2025073163A1
The present invention provides a method of treating an infectious disease. The method comprises the step of administering to a subject in need thereof an effective amount of (i) a polymer-flavonoid conjugate, (ii) a flavonoid oligomer, or (iii) micelles having a shell formed by one or more polymer-flavonoid conjugates or one or more flavonoid oligomers, or the combination thereof, and having an agent encapsulated within the shell. The present method is effective to treat viral infection, e.g., severe acute respiratory syndrome coronavirus (SARS-CoV), enterovirus virus, HIV, hepatitis B virus, MERS-CoV, influenza virus, Dengue virus, respiratory syncytial virus, hepatitis C virus, monkeypox virus, human papillomavirus, methicillin-resistant Staphylococcus aureus, Pseudomonas, tuberculosis, Bacillus anthracis, Tetani bacterium, Streptococcus pneumoniae, meningococcus, Escherichia coli, Legionella, Neisseria gonorrhea, Neisseria meningitidis, and Salmonella.
Resumen de: EP4516931A1
The present disclosure relates to a composition for preventing or treating coronavirus infection, including a hotspot-derived peptide-nucleic acid hybrid molecule. It was confirmed that in vitro evolution-based hotspot-derived peptide-nucleic acid hybrid molecule prepared using the method of the present invention has high binding affinity for the RBDs of SARS-CoV-2 VOCs (alpha, beta, gamma, delta, and omicron). In particular, it was found that the greatest binding tolerance was exhibited in the most highly mutated omicron. Furthermore, the hybrid molecule showed high RBD binding affinity in competition with RBD-binding nucleic acid aptamers, macrocyclic peptides, and monoclonal antibodies. The hybrid molecule also exhibited excellent nuclease resistance and serum stability, indicating potential as virus neutralizer in addition to SARS-CoV-2.
Resumen de: AU2023262192A1
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2, e.g., an infection in subject.
Resumen de: US2023355738A1
A bacteriophage T4-based, multivalent/multicomponent, needle and adjuvant-free, mucosal vaccine by engineering spike trimers on capsid exterior and nucleocapsid protein in the interior is disclosed herein. Intranasal administration of this T4-COVID vaccine induces higher virus neutralization antibody titers against multiple variants, balanced Th1/Th2 antibody and cytokine responses, stronger CD4+ and CD8+ T cell immunity, and higher secretory IgA titers in sera and bronchoalveolar lavage with no effect on the gut microbiota, compared to vaccination of mice intramuscularly. The vaccine is stable at ambient temperature, induce apparent sterilizing immunity, and provide complete protection against original SARS-CoV-2 strain and its Delta variant with minimal lung histopathology. This mucosal vaccine is an excellent candidate for boosting immunity of immunized and/or as a second-generation vaccine for the unimmunized population. This needle-free platform could be used to develop effective vaccines against many other respiratory infectious pathogens including Flu and any future emerging epidemic and pandemic pathogens.
Resumen de: EP4516301A2
The invention relates to specific compounds which are useful in treating coronavirus infections such as COVID-19.
Resumen de: PL446010A1
Niniejsze zgłoszenie dotyczy sposobu wykrywania w warunkach laboratoryjnych materiału genetycznego wirusa SARS-CoV-2 w próbce materiału biologicznego, sposobu diagnozowania in vitro zakażenia wirusem SARS-CoV-2 z wykorzystaniem takiego sposobu wykrywania materiału genetycznego wirusa SARS-CoV-2 oraz zestawu do wykrywania materiału genetycznego wirusa SARS-CoV-2 lub diagnozowania zakażenia wirusem SARS-CoV-2 w próbce materiału biologicznego w warunkach laboratoryjnych.
Resumen de: PL446009A1
Niniejsze zgłoszenie dotyczy sposobu wykrywania w warunkach nie-laboratoryjnych materiału genetycznego wirusa SARS-CoV-2 w próbce materiału biologicznego, sposobu diagnozowania in vitro zakażenia wirusem SARS-CoV-2 z wykorzystaniem takiego sposobu wykrywania materiału genetycznego wirusa SARS-CoV-2 oraz zestawu do wykrywania materiału genetycznego wirusa SARS-CoV-2 lub diagnozowania zakażenia wirusem SARS-CoV-2 w próbce materiału biologicznego w warunkach nie-laboratoryjnych.
Resumen de: AU2023320566A1
The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Resumen de: WO2025040122A1
A beta-coronavirus (β-CoV) recombinant chimeric antigen, a preparation method therefor and a use thereof. The β-CoV recombinant chimeric antigen is a chimeric dimer antigen formed by linking an RBD fragment of S protein of a SARS-CoV-2 Omicron variant BA.1 subtype or BA.2 subtype and an RBD fragment of S protein of SARS-CoV in series, which can not only stimulate an organism to generate high-level neutralizing antibodies against a SARS-CoV-2 prototype strain and various variants and against SARS-CoV, but also stimulate the organism to generate high-level neutralizing antibodies against other SARS-related coronaviruses, so that the β-CoV recombinant chimeric antigen is expected to become an immunogen for broad-spectrum vaccines against β-CoVs, and has great clinical application prospects and industrial values.
Resumen de: US2025066752A1
CRISPR RNA-guided nucleases are routinely used for sequence-specific manipulation of DNA. While CRISPR-based DNA editing has become routine, analogous methods for editing RNA have yet to be established. Here we repurpose the type III-A CRISPR RNA-guided nuclease for sequence-specific cleavage of the SARS-COV-2 genome. The type III cleavage reaction is performed in vitro using purified viral RNA, resulting in sequence-specific excision of 6, 12, 18 or 24 nucleotides. Ligation of the cleavage products is facilitated by a DNA splint that bridges the excision and RNA ligase is used to link the RNA products before transfection into mammalian cells. The SARS-COV-2 RNA is infectious and standard plaque assays are used to recover viral clones. Collectively, this work demonstrates how type III CRISPR systems can be repurposed for sequence-specific editing of RNA viruses including SARS-COV-2 and more generally for gene therapy.
Resumen de: US2025064950A1
The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to P-selectin. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are binders of P-selectin. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by a cell adhesion molecule, such as P-selectin, including vaso-occlusive crisis and sickle cell disease-related conditions, cancer, or COVID-19.
Resumen de: US2025064919A1
The disclosure is directed to a new human parainfluenza virus (HPIV)/SARS-CoV-2 vaccine or vaccine construct/polynucleotide. Specifically, the HPIV is a Human parainfluenza virus type 3 (HIPV3), and the vaccine construct encoding a SARS-CoV-2 spike protein (S protein), that is a SARS-CoV-2 S protein S1 subunit and/or a SARS-CoV-2 S protein receptor binding domain (RBD), in certain aspects the vaccine or vaccine construct is administered via intranasal administration.
Resumen de: US2025064789A1
A class of ketoamide derivatives and pharmaceutical uses thereof are provided. Specifically provided are the compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or an optical isomer thereof, or a deuterated compound thereof. The compound can effectively inhibit the activity of SARS-CoV-2 Mpro, and can be used in the manufacturer of SARS-CoV-2 Mpro inhibitors, blocking the replication and transcription of SARS-CoV-2 virus in patients. The compound can be used in preparing SARS-CoV-2 Mpro inhibitors, anti-SARS-CoV-2 medicaments, as well as the medicaments for preventing and/or treating Corona Virus Disease 2019 (COVID-19).
Resumen de: US2025064844A1
This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of human coronavirus 2019-nCoV.
Resumen de: US2025064795A1
Topotecan for use in the treatment of COVID-19 and/or its associated symptoms. Also disclosed is a method of treating an individual infected with a coronavirus, wherein said method comprises the steps of: providing Topotecan: and administering said Topotecan to said individual in a dosage amount sufficient to prevent/stabilize/reduce the risks and/or symptoms associated with a coronavirus infection.
Resumen de: US2025066740A1
A chimpanzee adenovirus vector from newly discovered and isolated chimpanzee adenovirus with unique HVR sequences and a method of its construction and application thereof, with higher viral titer, and provides a method for determining its viral titer. The chimpanzee adenovirus circular vector is constructed through a shuttle plasmid, and knocks out E1 and E3 to construct a replication-defective chimpanzee adenovirus vector. The chimpanzee adenovirus vector described in this article has no preexisting antibody in the population, and the knockout of E1 and E3 is safe. At the same time, it is significantly different from human adenovirus type 5 E1 in 293 cells, which can greatly avoid recovery mutation (RCA) and make it safer. The novel coronavirus vaccine has strong stability and does not cause mutations after multiple passages, and it can induce strong humoral immunity and cellular response in mouse models.
Resumen de: US2025066787A1
The present invention relates to a composition for administering a double-stranded oligonucleotide structure using an ultrasonic nebulizer. According to the method, the double-stranded oligonucleotide according to the present invention forms self-assembled nanoparticles, which are 90 nm in size and have a neutral charge, and it is possible to deliver the double-stranded oligonucleotide specifically to the nasal cavity and lungs while maintaining not only the same concentration, molecular weight, purity, nanoparticle size, and osmolality as those of the stock material but also the target gene inhibitory activity without cytotoxicity. Thus, the present invention may be useful for the prevention or treatment of respiratory viral infections including COVID-19, pulmonary fibrosis caused by viral infection, or respiratory diseases.
Resumen de: US2025066456A1
Infectious diseases remain a problem throughout the world. The outbreak of sudden acute respiratory syndrome coronavirus 2 (SARS-Co V-2) has infected more than 640 million people worldwide. SARS-Co V-2 causes the disease COVID-19. Mutations in the SARS-CoV-2 S spike protein enable SARS-CoV-2 variants to escape neutralizing monoclonal antibodies produced from previous infection with SARS-CoV2 or by vaccination. The present invention provides antibodies that bind to the SARS-Co V-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.
Resumen de: US2025066455A1
The present invention relates to antibodies or antigen-binding fragments thereof that neutralise SARS-CoV-2, and uses thereof.
Resumen de: US2025064888A1
The invention provides compositions and methods for treating, reducing or preventing cytokine storm, for example, in connection with a viral infection (e.g., by SARS-CoV-2), drug treatment or therapy, trauma or an inflammatory disease, or a related disease and disorder.
Nº publicación: US2025066365A1 27/02/2025
Solicitante:
KATHOLIEKE UNIV LEUVEN [BE]
Katholieke Universiteit Leuven
Resumen de: US2025066365A1
The invention relates to nucleoside derivatives of formula (I), wherein R has the same meaning as that defined in the claims and the description. The present invention also relates to pharmaceutical compositions comprising such compounds and to uses of such compounds and compositions for the treatment or prevention of viral infections, more in particular infections caused by RNA virus, such as coronavirus infections.
BOPI
Sede Electrónica
